• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 69-83 of 144,520 results

No. 275 SO ORDERED Granting (D.I. 51 in 23-cv-1103-RGA; D.I. 274 in 21-md-3017-RGA-LDH) STIPULATION ...

Document In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation, 1:21-md-03017, No. 275 (D.Del. Jun. 21, 2024)
WHEREAS, the parties seek additional time to continue discussing claim construction issues, and WHEREAS, the Court, at the parties’ request, moved the claim construction hearing by eight days, from October 3, 2024 to October 11, 2024; IT IS HEREBY STIPULATED AND AGREED, subject to the Court’s approval, that the remaining dates in the Scheduling Order (D.I.
cite Cite Document
Analyze

52 Notice Other: LEAP Request Granted

Document IPR2023-00480, No. 52 Notice Other - LEAP Request Granted (P.T.A.B. Jun. 6, 2024)
Petitioner is granted an additional fifteen minutes of argument time during the oral hearing, and reminded that the LEAP practitioner is required to have a meaningful and substantive opportunity to argue.
Petitioner has attached the required LEAP Request for Oral Hearing Participation and Practitioner Verification Forms certifying her eligibility.
If you are not an intended recipient or an authorized agent, you are hereby notified that reading, distributing, or otherwise disseminating or copying, or taking any action based on the contents of this transmission is strictly prohibited.
Hearing Information Requesting Party: Appeal/Case/Control Number: Hearing Date (mm/dd/yyyy): LEAP Practitioner Contact Information LEAP Practitioner Name: Firm Name: Street Address 1: Street Address 2: City: State/Province: Country: Email: Date: Zip/Postal Code: Phone Number: (Signature)
The applicable Privacy Act System of Records Notice for this information request is PAT-TM- 19, Dissemination Events and Registrations: Federal Register vol.
cite Cite Document
Analyze

52 Notice Other: LEAP Request Granted

Document IPR2023-00481, No. 52 Notice Other - LEAP Request Granted (P.T.A.B. Jun. 6, 2024)
Petitioner is granted an additional fifteen minutes of argument time during the oral hearing, and reminded that the LEAP practitioner is required to have a meaningful and substantive opportunity to argue.
Petitioner has attached the required LEAP Request for Oral Hearing Participation and Practitioner Verification Forms certifying her eligibility.
If you are not an intended recipient or an authorized agent, you are hereby notified that reading, distributing, or otherwise disseminating or copying, or taking any action based on the contents of this transmission is strictly prohibited.
Hearing Information Requesting Party: Appeal/Case/Control Number: Hearing Date (mm/dd/yyyy): LEAP Practitioner Contact Information LEAP Practitioner Name: Firm Name: Street Address 1: Street Address 2: City: State/Province: Country: Email: Date: Zip/Postal Code: Phone Number: (Signature)
The applicable Privacy Act System of Records Notice for this information request is PAT-TM- 19, Dissemination Events and Registrations: Federal Register vol.
cite Cite Document
Analyze

No. 170 SO ORDERED, D.I. 164 Stipulation to Extend the Case Schedule filed by Parse Biosciences, Inc., ...

Document Scale Biosciences, Inc. v. Parse Biosciences, Inc. et al, 1:22-cv-01597, No. 170 (D.Del. May. 30, 2024)
... of the parties to a date subsequent to that deadline as needed to accommodate deponent schedules; 1 Parse and UW do not agree with ScaleBio’s claim that any delay in the trial schedule would cause ScaleBio prejudice—certainly none ...
cite Cite Document
Analyze

50 Order Other: ORDER Setting Oral Argument

Document IPR2023-00480, No. 50 Order Other - ORDER Setting Oral Argument (P.T.A.B. May. 21, 2024)
Log in to see more
cite Cite Document
Analyze

50 Order Other: ORDER Setting Oral Argument

Document IPR2023-00481, No. 50 Order Other - ORDER Setting Oral Argument (P.T.A.B. May. 21, 2024)
Log in to see more
cite Cite Document
Analyze

No. 268 SO ORDERED Granting (D.I. 20 in 23-cv-1372-RGA; D.I. 267 in 21-md-03017-RGA-LDH) Stipulation ...

Document In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation, 1:21-md-03017, No. 268 (D.Del. May. 10, 2024)
Log in to see more
cite Cite Document
Analyze

Bayer Intellectual Property GMBH et al v. Taro Pharmaceutical Industries Ltd. et al

Docket 1:17-cv-00462, Delaware District Court (Apr. 21, 2017)
Judge Timothy Belcher Dyk, presiding
Patent
Log in to see more
cite Cite Docket
Analyze

Allergan Sales, LLC et al v. Teva Pharmaceuticals USA, Inc.

Docket 2:17-cv-00343, Texas Eastern District Court (Apr. 21, 2017)
Judge Rodney Gilstrap, presiding, Magistrate Judge Roy S. Payne
Patent
Log in to see more
cite Cite Docket
Analyze

No. 260 SO ORDERED Granting (D.I. 259 in 21-md-03017-RGA-LDH; D.I. 46 in 23-cv-01103-RGA) Stipulation ...

Document In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation, 1:21-md-03017, No. 260 (D.Del. Apr. 29, 2024)
Log in to see more
cite Cite Document
Analyze

3 Notice Notice filing date accorded: Notice Notice filing date accorded

Document IPR2024-00703, No. 3 Notice Notice filing date accorded - Notice Notice filing date accorded (P.T.A.B. Apr. 16, 2024)

cite Cite Document
Analyze

No. 163

Document Bayer Pharma AG et al v. Lupin Limited et al, 1:21-cv-00314, No. 163 (D.Del. Apr. 2, 2024)

cite Cite Document
Analyze

No. 256

Document In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation, 1:21-md-03017, No. 256 (D.Del. Apr. 2, 2024)

cite Cite Document
Analyze

No. 253

Document In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation, 1:21-md-03017, No. 253 (D.Del. Mar. 27, 2024)

cite Cite Document
Analyze

37 Order Other: ORDER Conduct of the Proceeding Granting Patent Owner’s Motio...

Document IPR2023-00480, No. 37 Order Other - ORDER Conduct of the Proceeding Granting Patent Owner’s Motion to Expunge Exhibit 2050 (P.T.A.B. Mar. 14, 2024)

cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 8 9 ... >>